

Borwin Bandelow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8383426/publications.pdf>

Version: 2024-02-01

157
papers

11,023
citations

36271

51
h-index

33869

99
g-index

189
all docs

189
docs citations

189
times ranked

10134
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of anxiety disorders in the 21st century. <i>Dialogues in Clinical Neuroscience</i> , 2015, 17, 327-335.	1.8	1,208
2	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 248-312.	1.3	661
3	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2005, 19, 567-596.	2.0	537
4	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014, 28, 403-439.	2.0	511
5	Treatment of anxiety disorders. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 93-107.	1.8	420
6	Efficacy of treatments for anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2015, 30, 183-192.	0.9	369
7	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 77-84.	1.2	327
8	Comparison of Aerobic Exercise, Clomipramine, and Placebo in the Treatment of Panic Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 603-609.	4.0	286
9	Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. <i>International Clinical Psychopharmacology</i> , 1995, 10, 73-82.	0.9	263
10	Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. <i>Psychiatry Research</i> , 2005, 134, 169-179.	1.7	263
11	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 162-214.	1.3	226
12	What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1428-1434.	1.1	177
13	Neuropeptide S receptor gene – converging evidence for a role in panic disorder. <i>Molecular Psychiatry</i> , 2011, 16, 938-948.	4.1	157
14	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 171-199.	1.3	155
15	Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 175-187.	1.3	131
16	TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. <i>Molecular Psychiatry</i> , 2011, 16, 647-663.	4.1	130
17	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 321-365.	1.3	118
18	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 305.	1.0	116

#	ARTICLE	IF	CITATIONS
19	Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 397-405.	1.8	110
20	Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. <i>Journal of Pineal Research</i> , 1995, 19, 116-122.	3.4	109
21	Borderline personality disorder: A dysregulation of the endogenous opioid system?. <i>Psychological Review</i> , 2010, 117, 623-636.	2.7	108
22	Which Factors Predict Placebo Response in Anxiety Disorders and Major Depression?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1741-1746.	1.1	108
23	WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults. <i>CNS Spectrums</i> , 2003, 8, 7-16.	0.7	103
24	Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1196-1204.	1.1	101
25	Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. <i>Neuroscience Letters</i> , 2003, 335, 179-182.	1.0	100
26	Rgs 2 gene polymorphisms as modulators of anxiety in humans?. <i>Journal of Neural Transmission</i> , 2006, 113, 1921-1925.	1.4	96
27	Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 769-781.	1.4	95
28	Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. <i>Comprehensive Psychiatry</i> , 2002, 43, 269-278.	1.5	93
29	Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 106-115.	2.2	93
30	WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. <i>CNS Spectrums</i> , 2003, 8, 53-61.	0.7	90
31	Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality. <i>Journal of Psychiatric Research</i> , 2010, 44, 930-937.	1.5	90
32	Neuroimaging in anxiety disorders. <i>Journal of Neural Transmission</i> , 2009, 116, 703-716.	1.4	85
33	Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 42-51.	1.7	83
34	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009, 24, 87-96.	0.9	82
35	The relevance of "mixed anxiety and depression" as a diagnostic category in clinical practice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 725-736.	1.8	82
36	Salivary Cortisol in Panic Attacks. <i>American Journal of Psychiatry</i> , 2000, 157, 454-456.	4.0	81

#	ARTICLE	IF	CITATIONS
37	WCA Recommendations for the Long-Term Treatment of Social Phobia. <i>CNS Spectrums</i> , 2003, 8, 40-52.	0.7	81
38	The German guidelines for the treatment of anxiety disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 363-373.	1.8	74
39	Plasma homocysteine is a predictor of alcohol withdrawal seizures. <i>NeuroReport</i> , 2000, 11, 2749-2752.	0.6	73
40	Attachment style, anxiety coping, and personality-styles in withdrawn alcohol addicted inpatients. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 1.	1.0	73
41	Safety and tolerance of zolpidem in the treatment of disturbed sleep. <i>International Clinical Psychopharmacology</i> , 1998, 13, 157-168.	0.9	70
42	The Diagnosis of and Treatment Recommendations for Anxiety Disorders. <i>Deutsches A&#x0308;rztblatt International</i> , 2014, 111, 473-80.	0.6	66
43	Nocturnal Melatonin Secretion and Sleep after Doxepin Administration in Chronic Primary Insomnia. <i>Pharmacopsychiatry</i> , 1996, 29, 187-192.	1.7	59
44	Salivary, total plasma and plasma free cortisol in panic disorder. <i>Journal of Neural Transmission</i> , 2000, 107, 831-837.	1.4	59
45	A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 904-913.	1.3	59
46	WCA Recommendations for the Long-Term Treatment of Panic Disorder. <i>CNS Spectrums</i> , 2003, 8, 17-30.	0.7	57
47	An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 510-516.	1.3	56
48	The Use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. <i>Pharmacopsychiatry</i> , 2000, 33, 174-181.	1.7	55
49	Current and Novel Psychopharmacological Drugs for Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 347-365.	0.8	55
50	Blood Dyscrasias Induced by Psychotropic Drugs. <i>Pharmacopsychiatry</i> , 2004, 37, 70-78.	1.7	54
51	Treatment-Resistant Panic Disorder. <i>CNS Spectrums</i> , 2004, 9, 725-739.	0.7	54
52	Exercise Avoidance and Impaired Endurance Capacity in Patients with Panic Disorder. <i>Neuropsychobiology</i> , 1997, 36, 182-187.	0.9	53
53	The use of the Panic and Agoraphobia Scale in a clinical trial. <i>Psychiatry Research</i> , 1998, 77, 43-49.	1.7	52
54	Chromosome 4q31â€34 panic disorder risk locus: Association of neuropeptide Y Y5 receptor variants. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 510-516.	1.1	52

#	ARTICLE	IF	CITATIONS
55	Diurnal variation of cortisol in panic disorder. <i>Psychiatry Research</i> , 2000, 95, 245-250.	1.7	51
56	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. <i>Human Psychopharmacology</i> , 2009, 24, 269-275.	0.7	51
57	Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder. <i>Journal of Neural Transmission</i> , 2000, 107, 1361-1366.	1.4	49
58	Separation Anxiety and Actual Separation Experiences during Childhood in Patients with Panic Disorder. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 948-952.	0.9	47
59	The Diagnosis and Treatment of Generalized Anxiety Disorder. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 300-9; quiz 310.	0.6	47
60	Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. <i>British Journal of Psychiatry</i> , 2018, 212, 333-338.	1.7	46
61	Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. <i>International Clinical Psychopharmacology</i> , 2000, 15, 153-161.	0.9	44
62	Decreased Neuroendocrine Responses to Meta-Chlorophenylpiperazine (m-CPP) but Normal Responses to Ipsapirone in Marathon Runners. <i>Neuropsychopharmacology</i> , 1999, 20, 150-161.	2.8	43
63	Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. <i>Psychopharmacology</i> , 2001, 155, 234-241.	1.5	43
64	Sertraline Versus Paroxetine in the Treatment of Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 405-413.	1.1	43
65	Myocarditis under therapy with clozapine. <i>Schizophrenia Research</i> , 1995, 17, 293-294.	1.1	42
66	WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. <i>CNS Spectrums</i> , 2003, 8, 31-39.	0.7	41
67	5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. <i>European Neuropsychopharmacology</i> , 2003, 13, 153-164.	0.3	40
68	The Medical Treatment of Obsessive-Compulsive Disorder and Anxiety. <i>CNS Spectrums</i> , 2008, 13, 37-46.	0.7	40
69	Zur sozialen Situation schizophrener Patienten. <i>Der Nervenarzt</i> , 1998, 69, 204-209.	5.0	39
70	Escitalopram in the treatment of anxiety symptoms associated with depression. <i>Depression and Anxiety</i> , 2007, 24, 53-61.	2.0	39
71	Panic disorder during pregnancy and postpartum period. <i>European Psychiatry</i> , 2006, 21, 495-500.	0.1	38
72	Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach. <i>CNS Spectrums</i> , 2006, 11, 21-28.	0.7	37

#	ARTICLE	IF	CITATIONS
73	Depressive syndromes in schizophrenic patients after discharge from hospital. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1990, 240, 113-120.	0.9	36
74	Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. <i>International Clinical Psychopharmacology</i> , 1995, 10, 83-94.	0.9	36
75	Clinically relevant drug interactions in anxiety disorders. <i>Human Psychopharmacology</i> , 2012, 27, 239-253.	0.7	36
76	Myocarditis Associated with Clozapine Treatment. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 880-880.	1.3	35
77	Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. <i>European Neuropsychopharmacology</i> , 1996, 6, 149-153.	0.3	34
78	Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo. <i>Pharmacopsychiatry</i> , 2007, 40, 152-156.	1.7	33
79	Cardio-respiratory and other symptom clusters in panic disorder. <i>Anxiety</i> , 1996, 2, 99-101.	0.5	32
80	Rebound insomnia after hypnotic withdrawal in insomniac outpatients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 148-156.	1.8	32
81	Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges. <i>Pharmacopsychiatry</i> , 2005, 38, 24-29.	1.7	30
82	Depressive syndromes in schizophrenic patients under neuroleptic therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 241, 291-295.	1.8	29
83	Urinary Excretion of Cortisol, Norepinephrine, Testosterone, and Melatonin in Panic Disorder. <i>Pharmacopsychiatry</i> , 1997, 30, 113-117.	1.7	28
84	<i>RGS2</i> genetic variation: Association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 211-222.	1.1	26
85	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 87-106.	1.8	26
86	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	1.3	26
87	Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine. <i>Pharmacopsychiatry</i> , 1998, 31, 117-121.	1.7	25
88	A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder. <i>Current Psychiatry Reports</i> , 2010, 12, 471-477.	2.1	25
89	Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. <i>Human Psychopharmacology</i> , 2015, 30, 393-415.	0.7	25
90	The German Guidelines for the treatment of anxiety disorders: first revision. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 571-582.	1.8	25

#	ARTICLE	IF	CITATIONS
91	Endurance Training in Panic Patients: Spiroergometric and Clinical Effects. <i>International Journal of Sports Medicine</i> , 1998, 19, 496-502.	0.8	24
92	Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. <i>Human Psychopharmacology</i> , 2011, 26, 614-628.	0.7	24
93	Treatment of Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2007, 12, 28-35.	0.7	23
94	Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospital. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 459-467.	1.8	23
95	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 5-18.	1.8	23
96	How to grade categories of evidence. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 242-247.	1.3	22
97	Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 557-566.	1.8	22
98	Association analysis of Rgs7 variants with panic disorder. <i>Journal of Neural Transmission</i> , 2009, 116, 1523-1528.	1.4	21
99	Manifesto for a European Anxiety Disorders Research Network. <i>European Neuropsychopharmacology</i> , 2010, 20, 426-432.	0.3	21
100	Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect?. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 66-70.	1.3	21
101	Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1733-1744.	1.0	21
102	Generalized Anxiety Disorder and Pain. <i>Modern Problems of Pharmacopsychiatry</i> , 2015, 30, 153-165.	2.5	21
103	The QT interval and the atypical antipsychotic, sertindole. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 265-273.	1.2	20
104	Gender Differences in Associations of Glutamate Decarboxylase 1 Gene (GAD1) Variants with Panic Disorder. <i>PLoS ONE</i> , 2012, 7, e37651.	1.1	20
105	What treatments do patients with panic disorder and agoraphobia get?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995, 245, 165-171.	1.8	19
106	Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks. <i>Molecular Psychiatry</i> , 2008, 13, 242-243.	4.1	19
107	Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. <i>BMC Psychiatry</i> , 2019, 19, 393.	1.1	19
108	Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 155-166.	1.3	17

#	ARTICLE	IF	CITATIONS
109	Sertraline and exposure therapy in social phobia. <i>British Journal of Psychiatry</i> , 2004, 184, 271-271.	1.7	16
110	The Use of Parametric vs. Nonparametric Tests in the Statistical Evaluation of Rating Scales. <i>Pharmacopsychiatry</i> , 1998, 31, 222-224.	1.7	15
111	A neurobiological framework of separation anxiety and related phenotypes. <i>European Neuropsychopharmacology</i> , 2020, 33, 45-57.	0.3	14
112	Nocturnal Urinary Cortisol Excretion Over a Randomized Controlled Trial with Paroxetine vs. Placebo Combined with Relaxation Training or Aerobic Exercise in Panic Disorder. <i>Current Pharmaceutical Design</i> , 2008, 14, 3518-3524.	0.9	13
113	Pharmacological Treatment of Panic Disorder. <i>Modern Problems of Pharmacopsychiatry</i> , 2013, 29, 128-143.	2.5	13
114	Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder. <i>Neuropsychopharmacology</i> , 2002, 27, 270-278.	2.8	12
115	Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. <i>CNS Spectrums</i> , 2017, 22, 404-406.	0.7	12
116	Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, 21-27.	1.8	11
117	Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. <i>Journal of Psychiatric Research</i> , 2010, 44, 1163-1169.	1.5	11
118	Efficacy of venlafaxine extended release in major depressive disorder patients. <i>International Clinical Psychopharmacology</i> , 2019, 34, 110-118.	0.9	11
119	Grey matter structural differences in alcohol-dependent individuals with and without comorbid depression/anxiety—an MRI study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 285-294.	1.8	11
120	Mean age and gender distribution of patients with major mental disorders participating in clinical trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 655-659.	1.8	11
121	Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson's disease and in neuroleptic treatment. <i>Vision Research</i> , 1997, 37, 3535-3547.	0.7	10
122	Wirksamkeitsuntersuchungen in der Psychotherapieforschung. <i>Verhaltenstherapie</i> , 2002, 12, 205-215.	0.3	10
123	Assessing the severity of panic disorder and agoraphobia. <i>Journal of Anxiety Disorders</i> , 2002, 16, 331-340.	1.5	10
124	"As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia—assessment of a novel intervention strategy in a primary care setting. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 1-7.	0.6	10
125	Anxiety symptom severity and functional recovery or relapse. <i>Annals of Clinical Psychiatry</i> , 2009, 21, 81-8.	0.6	9
126	The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 153-163.	1.8	8

#	ARTICLE	IF	CITATIONS
127	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm"; International Journal of Psychiatry in Clinical Practice, 2013, 17, 78-89.	1.2	8
128	Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients. Human Psychopharmacology, 2021, 36, e2800.	0.7	8
129	Chronic Pain and the Endocannabinoid System: Smart Lipids " A Novel Therapeutic Option?. Medical Cannabis and Cannabinoids, 2022, 5, 61-75.	1.2	8
130	Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: A pilot study with the binocular depth inversion paradigm. Psychology, Health and Medicine, 2013, 18, 363-374.	1.3	6
131	Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. European Psychiatry, 1995, 10, 173s-179s.	0.1	5
132	Clozapine-associated elevation of plasma cholinesterase. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 269-271.	1.8	5
133	Intermittent Medication, Coping and Psychotherapy Interactions in Relapse Prevention and Course Modification. British Journal of Psychiatry, 1992, 161, 140-144.	1.7	5
134	Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with depressive disorder and healthy controls. International Journal of Psychiatry in Clinical Practice, 2013, 17, 56-63.	1.2	4
135	Panic disorder " acceptance of the diagnostic entity and treatment modalities preferred by German health professionals. European Psychiatry, 1996, 11, 298-305.	0.1	3
136	Drug treatment for panic disorder. International Congress Series, 2006, 1287, 288-292.	0.2	3
137	Atypical Anorexia in a Male Patient Accompanied by Strong Obsessive-compulsive Symptoms Successfully Treated with Naltrexone. Pharmacopsychiatry, 2009, 42, 164-165.	1.7	3
138	Angst " Neurobiologie. , 2006, , 483-521.		3
139	Myocarditis associated with clozapine treatment. Australian and New Zealand Journal of Psychiatry, 2000, 34, 880-880.	1.3	3
140	Internet psychotherapeutic interventions for anxiety disorders " a critical evaluation. BMC Psychiatry, 2022, 22, .	1.1	3
141	Disorder-Specific Emotional Imagery for Differential and Quantitative Assessment of Agoraphobia. Current Pharmaceutical Design, 2012, 18, 5638-5644.	0.9	2
142	The myth that psychotherapy is more effective than pharmacotherapy in anxiety disorders. European Neuropsychopharmacology, 2021, 49, 116-118.	0.3	1
143	The application of the panic and Agoraphobia Scale (P & A) in clinical trials. European Psychiatry, 1998, 13, 283s-283s.	0.1	0
144	FC04.01 Responsiveness of central serotonin receptors in panic disorder: Effects of clomipramine treatment and exercise. European Psychiatry, 2000, 15, 243s-243s.	0.1	0

#	ARTICLE	IF	CITATIONS
145	S.2.6 Treatment of anxiety disorders. European Neuropsychopharmacology, 2005, 15, S96.	0.3	0
146	Pharmacological treatment of anxiety disorders - is there a state of the art?. European Psychiatry, 2007, 22, S90.	0.1	0
147	S.21.01 Treatment-resistant panic anxiety disorder. European Neuropsychopharmacology, 2007, 17, S207-S208.	0.3	0
148	How are symptom severity and functional recovery/relapse related? An analysis of the escitalopram database. European Psychiatry, 2008, 23, S369.	0.1	0
149	Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine. Movement Disorders, 2009, 24, 2431-2432.	2.2	0
150	Network analyses to rank pharmacological treatments for generalised anxiety disorder. Lancet, The, 2019, 393, 721-722.	6.3	0
151	Behandlungsprobleme bei Angstpatienten. , 2004, , 547-560.		0
152	Trastorno de angustia durante el embarazo y el periodo postparto. European Psychiatry (Ed EspaÃ±ola), 2007, 14, 44-50.	0.0	0
153	Reply to More on Placebo Response. Journal of Clinical Psychiatry, 2007, 68, 1984-1985.	1.1	0
154	Angsterkrankungen â€“ PanikstÃ¶rung, soziale und generalisierte AngststÃ¶rung (ICD-10 F4). , 2009, , 223-240.		0
155	Embitterment syndrome: Options for psychopharmacological management. , 2011, , 187-196.		0
156	In Reply. Deutsches Ärzteblatt International, 2013, 110, 610-1.	0.6	0
157	AngststÃ¶rungen im Alter. , 2017, , 199-217.		0